TrialThe Journal of infectious diseases2024

Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial.

Christine A Shaw et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.